This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vertex Pharma Swaps Endpoints in Key Cystic Fibrosis Studies

Vertex Pharmaceuticals (VRTX - Get Report) swapped around the primary and secondary endpoints of the two phase III clinical trials dubbed "Traffic" and "Transport" which are investigating combination therapy in cystic fibrosis patients.

The primary endpoint of both cystic fibrosis studies is now the absolute change in lung function, which before Thursday was a key secondary endpoint. Relative change in lung function was the primary endpoint but is now a key secondary endpoint.

The decision to swap out endpoints was made as "part of ongoing discussions with the FDA and was not based on anything going on in the study or anything observed in the study," said Vertex spokesman Zach Barber.

Barber added: "We consider this more procedural because we were always planning to measure and report both absolute and relative change endpoints. Nothing changes in terms of the powering of the study."

The "Traffic" and "Transport" studies investigate the combination of Kalydeco and VX-809 in cystic fibrosis patients with the F508del homozygous mutation. Results from these two studies are expected in mid-2014 and have the potential to deliver $6 billion or so in new sales to the company. To call these studies important for the future of Vertex's cystic fibrosis franchise is an understatement, and naturally, investors are paying very close attention to them.

Absolute change in lung function was the primary endpoint of the phase III studies which Vertex used to get Kalydeco approved for cystic fibrosis patients with the G551D mutation. With that said, Vertex executives in the past have talked about a 5% relative improvement in lung function as an important efficacy threshold for the Kalydeco-VX-809 combination therapy.

The "Traffic" and "Transport" studies are designed with 90% power to detect a 3% absolute and 5% relative improvement in lung function, measured by forced expiratory volume in 1 second (FEV1).

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs